Espansione Group announces new AI-powered algorithm for meibomian gland segmentation

News
Article

MeiboMetrics is scheduled to be available on several platforms starting in 2025.

Graphic of AI digital pathways Image credit: AdobeStock/ktsdesign

Image credit: AdobeStock/ktsdesign

A new algorithm powered with artificial intelligence (AI) for the segmentation and quantitative measurement of meibomian glands has been announced by Espansione Group.1 MeiboMetrics has been developed in partnership with the Institute of Biomedical and Neural Engineering at Reykjavik University, which was initiated in early 2023, according to a news release.

“The software is based on a novel approach that uses sophisticate bio-imaging techniques to measure and assess meibomian glands,” said Paolo Gargiulo, full professor, founder, and director at Reykjavick University’s Institute for Biomedical and Neural Engineering, in the release. “This new solution provides a quantitative evaluation of dry eye condition advancing the state-of-the-art technology in the field.”

The new algorithm is able to provide eye care providers with detailed data on length, width, and area of each meibomian gland, which also makes granular measurements possible. Additionally, MeiboMetrics utilizes AI to identify and segment meibomian glands, which then matches them against a large training dataset. This utilization of AI allows for better accuracy and provides repeatability while reducing the need for manual intervention, according to the release. Manual contouring is also not necessary, which reduces human error, maximizes repeatability of results, and streamlines clinical workflows.1

Currently, Espansione Group has developed a variety of different ophthalmic treatment and screening devices. Among those devices include eye-light for the treatment of dry age-related macular degeneration and extended anterior segment pathologies, meibomask for the management of anterior segment conditions including dry eye disease and meibomian gland dysfunction, and my-mask for the management of anterior segment conditions through photobiomodulation. The company’s devices utilize either Light Modulation Low=level Light Therapy (LM LLLT) or Optomal Power Energy. LM LLLT is a photobiomodulation technology which is utilized for the treatment of anterior and posterior segment conditions, while Optimal Power Energy is Espansione’s patented evolution of intense pulsed light technology.2

MeiboMetrics will be available on the me-check Pro and other platforms starting in 2025.1

References:
  1. Espansione Group announces MeibioMetrics: An innovative, AI-powered algorithm for meibomian gland segmentation and quantitative measurement. News release. Espansione Group. September 17, 2024. Accessed October 11, 2024. https://www.espansionegroup.it/newsroom/espansione-group-announces-meibometrics-an-innovative-ai-powered-algorithm-for-meibomian-gland-segmentation-quantitative-mea/
  2. A new paradigm in ophthalmology and beyond. Espansione Group. Accessed October 11, 2024. https://www.espansionegroup.it/

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
© 2025 MJH Life Sciences

All rights reserved.